Journal of the Korean Ophthalmological Society 2007;48(2):238-244.
Published online February 28, 2007.
Limbal Transplantation: A Midterm Clinical Outcome with Continuous Systemic Immune Suppression.
Eui Seok Han, Youn Seok In, Won Ryang Wee, Jin Hak Lee, Mee Kum Kim
1Department of Ophthalmology, Seoul National University College of Medicine1, Seoul, Korea. kmk9@snu.ac.kr
2Seoul Artificial Eye Center, Seoul National University Hospital Clinical Research Institute, Seoul, Korea.
3Department of Ophthalmology, Seoul National University Bundang Hospital, Seongnam, Korea.
전신면역억제를 지속한 각막윤부이식술 수여안의 중기 임상결과
한의석1,2,인연석1,2,위원량1,2,이진학2,3,김미금1,2
Department of Ophthalmology, Seoul National University College of Medicine1, Seoul, Korea Seoul Artificial Eye Center, Seoul National University Hospital Clinical Research Institute2, Seoul, Korea Department of Ophthalmology, Seoul National University Bundang Hospital3, Seongnam, Korea
Correspondence:  Eui Seok Han, M.D.1,2
Abstract
PURPOSE
To investigate the midterm outcome of limbal transplantation combined with continuous systemic immune suppression. METHODS: The medical records of 15 eyes in 14 patients who underwent limbal transplantation were reviewed retrospectively. All had been followed up for 6 months or more. Limbal transplantation was performed with 360 degrees of 0.19 mm partial corneal trephined tissues, accompanied with transient amniotic membrane transplantation. The procedure was accomplished with systemic cyclosporine or mycophenolate. We defined complete success as neither rejection nor epithelial defect; partial success as partial conjunctival ingrowth and neovascularization without epithelial defect; and graft failure as persistent epithelial defect or total conunctivalization with neovascularization. RESULTS: Mean age at surgery was 45.1 years. 9 eyes yielded complete success, 2 had partial success, and graft failure occurred in 4 on an average of 23.4 months postoperatively. Success including complete and partial success showed 67% incidence (4 of 6) of chemical burn, 33% (1 of 3) with Stevens-Johnson syndrome, and 100% (6 of 6) experienced another intractable ocular surface disease. Of 10 eyes (67%), which experienced graft rejection in an average of 2.7 months; 4 demonstrated full recovery with oral corticosteroid and enhanced immunosuppression, 2 presented with chronic graft rejection, and the other 4 ended in graft failure. CONCLUSIONS: Total success rate was revealed as 73.3% for on average 23.4 months in limbal transplantation with continuous systemic immune suppression, utilized for chronic intractable ocular surface disease.
Key Words: Graft rejection;Immune suppression;Immunosuppressant;Limbal transplantation
TOOLS
METRICS Graph View
  • 414 View
  • 6 Download
Related articles


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next